Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | KIF11 | P52732 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | SCN1A | P35498 | 2/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL372366 | 0.89 | KIF11 (0.49) | CYP1A2KMT2AMEN1CYP2D6MAPT | |
| SCHEMBL16586535 | 0.87 | CYP1A2 (0.47) | CYP1A2KMT2AMEN1CYP2D6MAPT | |
| SCHEMBL5793007 | 0.87 | KMT2A (0.50) | CYP1A2KMT2AMEN1CYP2D6MAPT | |
| SCHEMBL3664564 | 0.86 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6KIF11 | |
| SCHEMBL28419024 | 0.86 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6KIF11 | |
| SCHEMBL28419010 | 0.86 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6KIF11 | |
| SCHEMBL28416200 | 0.86 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6KIF11 | |
| SCHEMBL3664383 | 0.86 | CYP1A2 (0.46) | CYP1A2KMT2AMEN1CYP2D6KIF11 | |
| SCHEMBL2089245 | 0.84 | CYP1A2 (0.70) | CYP1A2KMT2AMEN1CYP2D6MAPT | |
| SCHEMBL305912 | 0.84 | CYP1A2 (0.70) | CYP1A2KMT2AMEN1CYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107033043-B | N- replaces benzenesulfonyl-substituted benzene formyl amine compound and its prepares the purposes of drug | 中国人民解放军第二军医大学 | 2019-04-30 | — | — | CN | claimed |
| CN-105418966-B | A kind of rubber additive and its preparation and application | 同济大学 | 2017-12-15 | — | — | CN | claimed |
| CN-107033043-A | N- replaces benzenesulfonyl-substituted benzene formyl amine compound and its prepares the purposes of medicine | 中国人民解放军第二军医大学 | 2017-08-11 | — | — | CN | claimed |
| CN-106749373-B | Rubber additive and preparation and application thereof | 同济大学 | 2020-06-26 | — | — | CN | disclosed |
| EP-3277671-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277670-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| EP-3277672-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | Bristol-Myers Squibb Company (US) | 2018-02-07 | — | — | EP | disclosed |
| CN-105418966-B | A kind of rubber additive and its preparation and application | 同济大学 | 2017-12-15 | — | — | CN | disclosed |
| CN-106749373-A | A kind of rubber additive and its preparation and application | 同济大学 | 2017-05-31 | — | — | CN | disclosed |
| WO-2016161286-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161279-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| WO-2016161269-A1 | INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE FOR THE TREATMENT OF CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-10-06 | — | — | WO | disclosed |
| US-8329926-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2012-12-11 | — | — | US | disclosed |
| US-8022083-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-7914776-B2 | Solid dispersions of opioid antagonists | ADOLOR CORPORATION (US) | 2011-03-29 | — | — | US | disclosed |
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-20090012037-A1 | Antiviral Compounds | GILEAD SCIENCE, INC. (US) | 2009-01-08 | — | — | US | disclosed |
| US-20070082053-A1 | Solid dispersions of opioid antagonists | ADOLOR CORPORATION (US) | 2007-04-12 | — | — | US | disclosed |
| WO-1992004045-A1 | NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275535-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | CYP1A2 4769/4885KMT2A 3571/4885MEN1 3488/4885 |
| US-20070082053-A1 | Solid dispersions of opioid antagonists | OPRK1, OPRD1, OPRM1 | CYP1A2 226/4885KMT2A 2218/4885MEN1 4883/4885 |
| US-20090012037-A1 | Antiviral Compounds | EIF2AK2, MAVS, ITPA | CYP1A2 4700/4885KMT2A 3924/4885MEN1 3603/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.